Stock TT5 XTACY THERAPEUTICS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Xtacy Therapeutics Corp. Deutsche Boerse AG

Equities

TT5

CA98423G1072

Investment Management & Fund Operators

Market Closed - Deutsche Boerse AG
Other stock markets
 07:04:45 10/05/2024 BST 		5-day change 1st Jan Change
0.011 EUR 0.00% Intraday chart for Xtacy Therapeutics Corp. -43.59% -12.00%
04-17 Xtacy Therapeutics Corp. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
04-15 Xtacy Therapeutics Corp. Reports Earnings Results for the Full Year Ended September 30, 2023 CI

Valuation

Fiscal Period: Septiembre 2018 2019 2020 2021 2022 2023
Capitalization 1 26.78 2.571 2.95 4.636 7.514 2.461
Enterprise Value (EV) 1 25.85 2.553 2.946 4.687 7.539 2.477
P/E ratio -7.44 x -1 x -2 x -1.09 x -3.97 x -4.19 x
Yield - - - - - -
Capitalization / Revenue - 22,896,953 x 28,958,998 x - - -
EV / Revenue - 22,734,144 x 28,919,742 x - - -
EV / EBITDA - - - - - -
EV / FCF 39.8 x -54.3 x -10.9 x 3.78 x -31.9 x -17 x
FCF Yield 2.51% -1.84% -9.18% 26.5% -3.14% -5.88%
Price to Book 36 x 4.22 x -11.3 x -10.8 x -16.7 x -7.33 x
Nbr of stocks (in thousands) 10,299 12,854 14,751 18,545 37,568 49,215
Reference price 2 2.600 0.2000 0.2000 0.2500 0.2000 0.0500
Announcement Date 28/01/19 28/01/20 28/01/21 02/02/22 29/03/23 15/04/24
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Septiembre 2018 2019 2020 2021 2022 2023
Net sales - 0.1123 0.1019 - - -
EBITDA - - - - - -
EBIT 1 -3.191 -2.204 -1.447 -3.589 -0.7838 -0.4878
Operating Margin - -1,963.23% -1,420.44% - - -
Earnings before Tax (EBT) 1 -3.303 -2.37 -1.375 -3.584 -1.369 -0.5199
Net income 1 -3.303 -2.37 -1.375 -3.584 -1.369 -0.5199
Net margin - -2,111.26% -1,349.72% - - -
EPS 2 -0.3496 -0.2000 -0.1000 -0.2300 -0.0504 -0.0119
Free Cash Flow 1 0.6492 -0.047 -0.2706 1.24 -0.2364 -0.1456
FCF margin - -41.89% -265.6% - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 28/01/19 28/01/20 28/01/21 02/02/22 29/03/23 15/04/24
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: Septiembre 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - 0.05 0.03 0.02
Net Cash position 1 0.93 0.02 0 - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 0.65 -0.05 -0.27 1.24 -0.24 -0.15
ROE (net income / shareholders' equity) -817% -350% -788% 921% 283% 133%
ROA (Net income/ Total Assets) -337% -148% -234% -15,143% -303% -91.7%
Assets 1 0.9809 1.602 0.5879 0.0237 0.4518 0.5673
Book Value Per Share 2 0.0700 0.0500 -0.0200 -0.0200 -0.0100 -0.0100
Cash Flow per Share 2 0.0900 0 0 0 - -
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 28/01/19 28/01/20 28/01/21 02/02/22 29/03/23 15/04/24
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Investment Management & Fund Operators

1st Jan change Capi.
BLACKROCK, INC. Stock BlackRock, Inc.
-1.86% 118B
UBS GROUP AG Stock UBS Group AG
+3.26% 95.3B
BROOKFIELD CORPORATION Stock Brookfield Corporation
+13.75% 69.05B
APOLLO GLOBAL MANAGEMENT, INC. Stock Apollo Global Management, Inc.
+20.25% 63.76B
BANK OF NEW YORK MELLON CORPORATION (THE) Stock Bank of New York Mellon Corporation (The)
+12.28% 43.7B
AMERIPRISE FINANCIAL, INC. Stock Ameriprise Financial, Inc.
+14.14% 43.06B
3I GROUP PLC Stock 3i Group plc
+17.76% 34.41B
T. ROWE PRICE GROUP INC. Stock T. Rowe Price Group Inc.
+3.63% 24.92B
STATE STREET CORPORATION Stock State Street Corporation
-1.14% 23.07B
Other Investment Management & Fund Operators
  1. Stock Market
  2. Equities
  3. XTCY Stock
  4. TT5 Stock
  5. Financials Xtacy Therapeutics Corp.